Dong Youyi, Sui Li, Watanabe Yasuo, Yamaguchi Fuminori, Hatano Naoya, Tokuda Masaaki
Department of Cell Physiology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Clin Cancer Res. 2005 Jan 1;11(1):259-66.
Jun activation domain-binding protein 1 (Jab1) is known as a coactivator of AP1 transcription factor, which contributes to tumor progression by degrading the p27kip1 protein. The purpose of this study is to investigate whether Jab1 expression is correlated with p27kip1 level and cell proliferation, as well as whether Jab1 expression is associated with clinicopathologic variables and prognosis of laryngeal squamous cell carcinoma (LSCC).
Immunohistochemical and/or Western blot analysis was done in HEp-2 cells and 102 cases of LSCCs.
Jab1 expression was negatively associated with p27kip1 expression and was positively associated with cell proliferation both in HEp-2 cells and LSCCs. Jab1 overexpression was detected in 51% LSCCs and was significantly associated with unfavorable clinicopathologic variables. Survival analysis revealed that Jab1 overexpression is significantly associated with short disease-free and overall survival (P = 0.0036 and P = 0.0001, respectively). When Jab1 and p27kip1 are combined, patients with Jab1(+)/p27kip1(-) revealed poor disease-free and overall survival (P= 0.0008 and P < 0.0001, respectively). When Jab1 expression and lymph node status are combined, patients with Jab1(+)/lymph node(+) revealed poorer disease-free andoverall survival than others (P < 0.0001 and P < 0.0001, respectively). Furthermore, patients with the phenotype of Jab1(+)/p27kip1(-)/lymph node(+) revealed the worst disease-free and overall survival (P < 0.0001 and P < 0.0001, respectively). Multivariate analysis revealed that Jab1 protein is an independent prognostic indicator for overall survival.
These findings suggested that Jab1 protein may contribute to the tumor progression and represent a novel prognostic indicator for LSCCs.
Jun激活域结合蛋白1(Jab1)是AP1转录因子的一种共激活因子,它通过降解p27kip1蛋白促进肿瘤进展。本研究旨在探讨Jab1表达是否与p27kip1水平及细胞增殖相关,以及Jab1表达是否与喉鳞状细胞癌(LSCC)的临床病理变量及预后相关。
对HEp-2细胞和102例LSCC病例进行免疫组织化学和/或蛋白质印迹分析。
在HEp-2细胞和LSCC中,Jab1表达与p27kip1表达呈负相关,与细胞增殖呈正相关。51%的LSCC中检测到Jab1过表达,且与不良临床病理变量显著相关。生存分析显示,Jab1过表达与无病生存期和总生存期短显著相关(分别为P = 0.0036和P = 0.0001)。当Jab1和p27kip1联合分析时,Jab1(+)/p27kip1(-)的患者无病生存期和总生存期较差(分别为P = 0.0008和P < 0.0001)。当Jab1表达和淋巴结状态联合分析时,Jab1(+)/淋巴结(+)的患者无病生存期和总生存期比其他患者差(分别为P < 0.0001和P <